Royalty Pharma plc
Royalty Pharma buys biopharmaceutical royalties and funds innovations in the US. It acquires and evaluates royalties on various therapies. The company collaborates with innovators from academia, research hospitals, and industry companies. Its portfolio includes royalties on 35 commercial products and 14 development-stage candidates across various therapeutic areas. Founded in 1996, Royalty Pharma is based in New York City.
Overview
Strengths
- Return on invested capital has stayed above 15% in each of the last 6 years (latest 16.1%), a hallmark of a durable competitive advantage.
- Creates economic value: ROIC of 16.1% against a cost of capital (WACC) of 6.2%, a spread of 9.9 percentage points.
- High-quality earnings: over the last 6 years, free cash flow added up to 328% of reported net income.
- Valued below its Biotechnology peers: P/FCF 11.6x vs. a median of 20.2x.
- EBITDA margin of 67.8% beats 95% of its 128 Biotechnology peers (median 0.0%).
Weaknesses
- High leverage: net debt is 5.2x EBITDA, against a median of 0.5x for its Biotechnology peers.
- Valued at a premium to its Biotechnology peers: P/E 37.6x vs. a median of 19.2x and EV/EBITDA 23.1x vs. a median of 15.0x.
- More expensive than its own history: EV/EBITDA 23.1x vs. a historical average of 15.9x.
Key Financial Data